OVERVIEW

2018 Virtual Symposium: Cardiovascular Risk Reduction in T2DM: Applying the Trial Data to Clinical Practice is organized by Tarsus CNS.

Intended Audience:
US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, and other allied health professionals.

Credit Designation Statement(s):
Physician Credit Designation
Global Education Group designates this virtual activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education:
Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

There are 1.0 pharmacotherapy hours available for this activity.

Credit Designation:
Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. This is a knowledge based activity. Universal Activity Number (UAN): 0530-9999-18-430-H01-P

Dietician Accreditation Statement:
Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.0 Continuing Professional Education units (CPEUs) for completion of this activities / materials.

Program Description:
Death from CV disease is 70% higher in adults with diabetes compared to those without diabetes, and patients with diabetes have a decreased life expectancy, mostly due to premature CV death. Evidence is accumulating that other factors besides impaired glucose metabolism play a role in the pathophysiology of T2DM and that a comprehensive approach against insulin resistance, obesity, hypertension, and dyslipidemia in addition to diet and exercise is required. In addition, because certain pharmacologic therapies were found to increase the risk of CV events, all new drugs introduced since 2008 have been mandated by the FDA to undergo CV safety outcome trials (CVOT) in high-risk T2DM patients. As a result, a growing body of evidence is accumulating on the effectiveness of several antihyperglycemic agents to reduce CV mortality, overall mortality, and hospitalizations for worsening heart failure in high-risk patients with T2DM.

In this virtual symposium, recorded from the 13th Annual Cardiometabolic Health Congress, experts will utilize a unique, infographic teaching format to review the latest cardiovascular outcomes studies of current antihyperglycemic therapies and compare the risks vs benefits as well as how to incorporate them into an individualized treatment plan for clinicians who treat patients with T2DM who are at a high risk for CVD.

Educational Objectives:
Upon completion of this activity, participants should be able to:
• Describe comorbidities of CVD among patients with T2DM, including the prevalence and burden
• Summarize current and emerging CV outcomes trials on SGLT2 inhibitors and GLP1-RAs in T2DM patients
• Incorporate evidence from recent CVOTs to develop T2DM treatment plans that improve glycemic control and reduce CV risk when appropriate based on guidelines, benefits and risks of second-line antihyperglycemic treatments, and patient profiles and preferences.

FACULTY

Harold Bays

MD, MFOMA, FTOS, FACC, FNLA, FASPC, DABOMEndocrinology, Diabetes and Metabolism, Internal Medicine

Deepak Bhatt

MD, MPH, MBA, FACC, FAHA, FESC, MSCAICardiology, Cardiovascular Disease, Internal Medicine, Interventional Cardiology

Lawrence Blonde

MD, FACP, MACEInternal Medicine, Nuclear Medicine, Endocrinology, Metabolism and Diabetes

SPECIALITIES

Cardiology

CANCELLATION & REFUND POLICY

This is our canceling policy

Cancellations must be submitted in writing. If you are calling to cancel, for verification we will still require you to send an email to info@brainweek.org with your intent to cancel. You will receive confirmation of your cancellation via email.

We will offer a 100% refund within 72 hours from the time of purchase less $100 credit card processing fee.

After 72 hours, refunds will be less 50%. All refund requests must be made in writing and post marked or tax stamped no later than 90 days before the event.

No refund will be made if the request is made within 90 days of the educational event. Refunds will not be issued to non-show registrants.

Substitutions are always welcome in lieu of cancellation. No transfers to alternate events will be made if the request is submitted within 90 days of the original event.

Persons who register and fail to attend will not receive a refund. BRAINWeek, at its sole discretion, may transfer your registration to an upcoming conference or to a healthcare provider colleague. Cancellation of your conference registration does not automatically cancel your hotel room reservation. Please contact the hotel to cancel your room; penalties may apply.